41
Participants
Start Date
March 2, 2021
Primary Completion Date
August 2, 2022
Study Completion Date
August 2, 2022
hAd5-S-Fusion+N-ETSD vaccine
The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
Khayelitsha Clinical Research Site, Khayelitsha
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY